New insights could lead to a better pneumococcal vaccine

September 23, 2008

Discovery of a new, previously unknown mechanism of immunity suggests that there may be a better way to protect vulnerable children and adults against Streptococcus pneumoniae (pneumococcal) infection, say researchers at Children's Hospital Boston and Harvard School of Public Health (HSPH). The findings, published in the open-access journal PLoS Pathogens on September 19, may aid the development of novel pneumococcal vaccines. (The current vaccine, Prevnar, is expensive and covers only 7 of the 91 known pneumococcal strains.)

Pneumococcus causes serious infections in children and the elderly, including pneumonia and meningitis (inflammation of the brain). Since 2000, U.S. infants have been routinely immunized against pneumococcus, but most developing countries (where nearly one million children die from pneumococcal infections annually) cannot afford the existing vaccine.

Richard Malley, MD, of Children's Division of Infectious Diseases, and Marc Lipsitch, D. Phil., of HSPH have been studying how natural immunity against pneumococcus develops, and have shown that in addition to antibodies, T-cells can provide broad protection against this pathogen. In this new study, Malley and Lipsitch identify the specific protective T-cells - so-called TH17 cells - and show that they protect against infection by releasing IL-17, a protein that enables human blood cells to kill pneumococcus in the nose more efficiently. This is significant, since colonizing a person's nose is the first necessary step of infection.

Researchers had known that children, as they get older, carry pneumococcus in the nose for shorter periods of time and have less risk of disease, but it hadn't been known how this resistance develops. Malley, Lipsitch and their colleagues now show that adults and older children, but not newborn babies, have TH17 cells that target pneumococci, suggesting that exposure to pneumococcus normally leads to production of these cells. In mice, they show directly that exposure to pneumococcus triggers the development of these T cells and shortens the duration of nasal carriage of the pathogen.

The investigators also describe an efficient way of measuring TH17 cells, which could help determine whether a new vaccine is rallying an effective response. "We are now evaluating vaccine candidates and changing them so they not only induce antibodies, but also induce this specific type of immunity," says Malley. "A vaccine that induces both protective antibodies and T-cell immunity to pneumococcus may be a very effective way to protect against this potentially devastating disease."
Malley's own lab is developing an inexpensive whole-cell pneumococcal vaccine that elicits a robust TH17 response in mice. With support from the Program for Appropriate Technology in Health (PATH), a nonprofit group funded in part by the Bill and Melinda Gates Foundation, the vaccine is being manufactured for future human testing by Instituto Butantan, a manufacturer in Brazil. Malley's laboratory is testing various forms of the vaccine in animals, including nasal and oral versions. The advantage of a whole-cell vaccine is that it can broadly protect against all pneumococcal strains and would be very inexpensive to produce and administer.

Malley believes the ability to induce protective T-cell responses may have relevance for other infections of childhood, such as Staphylococcus aureus and Haemophilus influenzae. Such responses are also being evaluated in pathogens against which antibodies are ineffective, such as herpes simplex, malaria and tuberculosis.

The study was funded by PATH and the National Institutes of Health.

Citation: Lu Y-J; et al. Interleukin-17A Mediates Acquired Immunity to Pneumococcal Colonization. PLoS Pathogens, September 19, 2008.

Children's Hospital Boston

---

---

	Pneumococcal Vaccines: The Impact of Conjugate Vaccine by Keith P. Klugman (Editor), P. Helena Makela (Editor), George R. Siber (Editor) * Explains how to monitor and measure the effects of pneumococcal conjugate vaccine introduction * Summarizes the most current information on pneumococcal conjugate vaccines * Discusses the world-wide potential of the vaccines * Details the impact of vaccination on childhood respiratory disease, including antibiotic resistance * Makes clear the biology of the pneumococcus in relation to disease * Explains the dynamics of a successful vaccine launch
	Pneumococcal immunization coverage has jumped to 80%.: An article from: Family Practice News by Alicia Ault (Author) This digital document is an article from Family Practice News, published by Thomson Gale on October 15, 2006. The length of the article is 522 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Pneumococcal immunization coverage has jumped to 80%. Author: Alicia Ault Publication: Family Practice News (Magazine/Journal) Date: October 15, 2006 Publisher: Thomson Gale Volume: 36 Issue: 20 Page: 25(1) Distributed by Thomson...
	The Pneumococcus and the Pneumococcal Vaccine (Studies in infectious disease research) by Paul G. Quie (Author), Edward H. Kass (Author)
	Vaccine Safety Manual for Concerned Families and Health Practitioners, 2nd Edition: Guide to Immunization Risks and Protection by Neil Z. Miller (Author), Russell Blaylock (Foreword) The Vaccine Safety Manual (new, updated 2012 edition) is the world's most complete guide to immunization risks and protection. It includes pertinent information on every major vaccine: polio, tetanus, MMR, hepatitis A, B, HPV (cervical cancer), Hib, Flu, chickenpox, shingles, rotavirus, pneumococcal, meningococcal, RSV, DTaP, anthrax, smallpox, TB, and more. All of the information, including detailed vaccine safety and efficacy data, is written in an easy-to-understand format, yet includes more than 1,000 scientific citations. More than 100 charts, tables, graphs and illustrations supplement the text. This encyclopedic health manual is an important addition to every family's home library and will be referred to again and again.
	The Vaccine Guide: Risks and Benefits for Children and Adults by Randall Neustaedter (Author) The Vaccine Guide covers each disease and its vaccine, providing difficult-to-obtain facts about vaccine reactions. Also discussed are vaccine effectiveness, toxicity and adverse effects, legal requirements, alternatives, and the latest information on the threat of bioterrorism. New to this edition are topics of particular concern to adults, including smallpox and anthrax vaccines, flu shots, and new conditions linked to vaccine reactions.
	Fourth dose of PCV7 vaccine suspended due to shortage: supplies limited until July.(News)(7-valent pneumococcal conjugate vaccine): An article from: Family Practice News by Heidi Splete (Author) This digital document is an article from Family Practice News, published by International Medical News Group on March 1, 2004. The length of the article is 510 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Fourth dose of PCV7 vaccine suspended due to shortage: supplies limited until July.(News)(7-valent pneumococcal conjugate vaccine) Author: Heidi Splete Publication: Family Practice News (Magazine/Journal) Date: March 1, 2004 Publisher: International Medical News Group Volume: 34 Issue: 5 Page: 4(1) Distributed by Thomson...
	Rare systemic dermatologic reaction after pneumococcal vaccine administration. (Case Report).: An article from: Southern Medical Journal by Mack R. Holdiness (Author) This digital document is an article from Southern Medical Journal, published by Southern Medical Association on January 1, 2003. The length of the article is 1502 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Rare systemic dermatologic reaction after pneumococcal vaccine administration. (Case Report). Author: Mack R. Holdiness Publication: Southern Medical Journal (Refereed) Date: January 1, 2003 Publisher: Southern Medical Association Volume: 96 Issue: 1 Page: 64(2) Distributed by Thomson...
	Conjugate pneumococcal vaccine benefits extend to adult contacts. ('Stand Up and Cheer').: An article from: Internal Medicine News by Nancy Walsh (Author) This digital document is an article from Internal Medicine News, published by International Medical News Group on June 1, 2003. The length of the article is 1597 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Conjugate pneumococcal vaccine benefits extend to adult contacts. ('Stand Up and Cheer'). Author: Nancy Walsh Publication: Internal Medicine News (Magazine/Journal) Date: June 1, 2003 Publisher: International Medical News Group Volume: 36 Issue: 11 Page: 45(1) Distributed by Thomson...
	Many adult diabetics not getting vaccines: pneumococcal, flu. (Infectious Diseases).: An article from: Internal Medicine News by Sharon Worcester (Author) This digital document is an article from Internal Medicine News, published by International Medical News Group on July 1, 2003. The length of the article is 451 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Many adult diabetics not getting vaccines: pneumococcal, flu. (Infectious Diseases). Author: Sharon Worcester Publication: Internal Medicine News (Magazine/Journal) Date: July 1, 2003 Publisher: International Medical News Group Volume: 36 Issue: 13 Page: 32(1) Distributed by Thomson...
	Pneumococcal vaccine is a must for cochlear implant patients: 30-fold higher risk in this population. (News).: An article from: Pediatric News by Miriam E. Tucker (Author) This digital document is an article from Pediatric News, published by International Medical News Group on July 1, 2003. The length of the article is 362 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Pneumococcal vaccine is a must for cochlear implant patients: 30-fold higher risk in this population. (News). Author: Miriam E. Tucker Publication: Pediatric News (Magazine/Journal) Date: July 1, 2003 Publisher: International Medical News Group Volume: 37 Issue: 7 Page: 6(1) Distributed by Thomson...